References
- Kenemans P, Barentsen R, van de Weijer P, eds. Practical HRT. Bussum, The Netherlands: Medicom, 1995
- Barrett-Connor E. Hormone replacement therapy. Br Med J 1998;317:457–61
- Soderqvist G. Effects of sex steroids on prolifer-ation in normal mammary tissue. Ann Med 1998;30:511–24
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 without breast cancer. Lancet 1997;350:1047–59
- Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen and oestrogen—progestin replacement therapy. Int J Cancer 1999;81:339–44
- Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
- Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
- Nystrom L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet 1993;341: 973–8
- Marugg RC, van der Mooren MJ, Hendriks JH, et al. Mammographic changes in post-menopausal women on hormonal replacement therapy. Eur Radiol 1997;7:749–55
- Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen—progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201–7
- Lundstrom E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181: 348–52
- Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen—progestin on mammo- graphic parenchymal density. Ann Intern Med 1999;130:262— 9
- Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prey 1998;7: 1133–44
- Wolfe JN. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976;26:1130–9
- Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486–92
- Weissberger AJ, Ho KY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hor-mone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72: 374–81
- von Schoultz B, Carlström K. On the regulation of sex-hormone-binding globulin — a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biocbem 1989;32:327–34
- Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999;140:5075–81
- Lippworth L, Adami H-0, Trichopoulos D, et al. Serum steroid hormone levels, sex hormone-binding globulin and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7:96–100
- Cardozo L, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998;105:403–7
- Weiderpass E, Baron JA, Adami H-0, et al. Low potency oestrogen and risk of endometrial cancer: a case—control study. Lancet 1999;353: 1824–8
- Preston Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–21
- Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999;106:1006–18
- Söderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123–8
- Cline M, Söderqvist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal macaques. Am J Obstet Gynecol 1996;174: 93–100
- Hofseth LG, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Gun Endocrinol Metab 1999;84:4559–65
- Wren BG, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 1996;3:4–12